Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04977453
Recruitment Status : Recruiting
First Posted : July 27, 2021
Last Update Posted : November 5, 2021
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
GI Innovation, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2025